Literature DB >> 32516066

Diabetes mellitus as a vaccine-effect modifier: a review.

Thomas Verstraeten1, Mark A Fletcher2, Jose A Suaya3, Sally Jackson1, Cassandra K Hall-Murray4, Daniel A Scott5, Beate Schmöle-Thoma6, Raul E Isturiz4, Bradford D Gessner3.   

Abstract

INTRODUCTION: Diabetes mellitus (DM) is a highly prevalent, chronic condition in adults worldwide. Little is known about the potential role of diabetes as an effect modifier of vaccine protective responses. AREAS COVERED: We conducted a literature review of the immunogenicity, efficacy and effectiveness of immunization in individuals, in studies that compared subjects with DM (DM+) and without DM (DM-). We found few published studies, which were only for vaccines against hepatitis B, influenza, pneumococcal disease, or varicela zoster. Except for a consistent attenuation of the immune response to hepatitis B vaccine among DM+ individuals, we found little other consistent evidence for DM as an effect modifier of vaccine responses. EXPERT OPINION: There are substantial gaps in our knowledge of the impact of DM on the immune response to immunization or effect of vaccination.

Entities:  

Keywords:  Diabetes mellitus; effect modifier; effectiveness; efficacy; immunogenicity

Mesh:

Substances:

Year:  2020        PMID: 32516066     DOI: 10.1080/14760584.2020.1760098

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  6 in total

1.  Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: The prospective COVAC-DM cohort study.

Authors:  Caren Sourij; Norbert J Tripolt; Faisal Aziz; Felix Aberer; Patrick Forstner; Anna M Obermayer; Harald Kojzar; Barbara Kleinhappl; Peter N Pferschy; Julia K Mader; Gerhard Cvirn; Nandu Goswami; Nadine Wachsmuth; Max L Eckstein; Alexander Müller; Farah Abbas; Jacqueline Lenz; Michaela Steinberger; Lisa Knoll; Robert Krause; Martin Stradner; Peter Schlenke; Nazanin Sareban; Barbara Prietl; Susanne Kaser; Othmar Moser; Ivo Steinmetz; Harald Sourij
Journal:  Diabetes Obes Metab       Date:  2022-01-24       Impact factor: 6.408

2.  Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.

Authors:  Amir Bahador Boroumand; Mahtab Forouhi; Farzaneh Karimi; Arman Soltani Moghadam; Leila Ghanbari Naeini; Pajman Kokabian; Delaram Naderi
Journal:  Front Immunol       Date:  2022-08-29       Impact factor: 8.786

Review 3.  The Nature of Immune Responses to Influenza Vaccination in High-Risk Populations.

Authors:  Kristin B Wiggins; Maria A Smith; Stacey Schultz-Cherry
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

Review 4.  PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).

Authors:  Christian Theilacker; Mark A Fletcher; Luis Jodar; Bradford D Gessner
Journal:  Microorganisms       Date:  2022-01-08

5.  Immunogenicity of SARS-CoV-2 BNT162b2 Vaccine in People with Diabetes: A Prospective Observational Study.

Authors:  Eleni Papadokostaki; Anastasios Tentolouris; Ioanna A Anastasiou; Mina Psichogiou; Evangelia Iliaki; Ioanna Eleftheriadou; Angelos Hatzakis; Nikolaos Tentolouris
Journal:  Vaccines (Basel)       Date:  2022-03-02

6.  Antibody response to multiple antigens of SARS-CoV-2 in patients with diabetes: an observational cohort study.

Authors:  Vito Lampasona; Massimiliano Secchi; Marina Scavini; Elena Bazzigaluppi; Cristina Brigatti; Ilaria Marzinotto; Alberto Davalli; Amelia Caretto; Andrea Laurenzi; Sabina Martinenghi; Chiara Molinari; Giordano Vitali; Luigi Di Filippo; Alessia Mercalli; Raffaella Melzi; Cristina Tresoldi; Patrizia Rovere-Querini; Giovanni Landoni; Fabio Ciceri; Emanuele Bosi; Lorenzo Piemonti
Journal:  Diabetologia       Date:  2020-10-08       Impact factor: 10.122

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.